Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

Release date May. 04, 2023, 07:30 am EDT
Dubai, United Arab Emirates
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
Dubai Science Park

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it established a regional headquarters at Dubai Science Park, a member of TECOM Group PJSC.

The office space is located in the heart of the global science-focused community that enables research, innovation and businesses in the health, energy, life sciences and environment sectors. The new headquarters will accommodate the company's expansion into the Middle East and improve global operations by attracting local partnerships and talents.

By entering the region, Virax Biolab Group aims to increase its distribution reach of high-quality in-vitro diagnostics, innovative products and proprietary T-Cell tests while creating logistical efficiencies. The new headquarters will create new jobs and drive investment and talent to the UAE in line with the Dubai Economic Agenda 'D33'.

"The addition of a regional headquarters in Dubai Science Park aligns perfectly with our mission to bring world-class testing solutions for viral threats to additional geographies," said James Foster, Virax's Chairman of the Board of Directors and Chief Executive Officer. "The new headquarters will strengthen the distribution network we have developed for ViraxClear and enable further development of our innovative technology behind Virax Immune, while tapping into an esteemed science and business community established at Dubai Science Park."

"We are excited to be a part of Dubai Science Park," said Cameron Shaw, Virax's Chief Operations Officer. "As a fast-growing company with a mission to establish global reach and enhance immune health, we hope to take advantage of the full spectrum of benefits at our disposal at Dubai Science Park while contributing to an ecosystem that is driving global change in business and healthcare."

Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park – TECOM Group, said: "Dubai's status as a global medical destination has secured the trust of patients and healthcare service providers alike. Innovative businesses are increasingly choosing our district to expand operations to benefit the lives and treatment of countless patients across the UAE and the region. We are delighted to welcome Virax Biolabs Group to our fast-growing science community. We are certain their cutting-edge detection and treatment services will strengthen Dubai's healthcare ecosystem and help achieve the vision of 'We The UAE 2031'."

Dubai Science Park is a global ecosystem that serves the entire value chain of the science, health and pharma sectors. Home to global MNEs, SMEs and start-ups, the hub contributes to Dubai's knowledge and innovation economy and its status as a medical tourism destination. Dubai Science Park provides businesses with purpose-built infrastructure to foster growth and access to markets across the UAE as well as the MENA region.

Dubai Science Park is part of TECOM Group's portfolio of 10 districts that includes Dubai Internet City, Dubai Media City, Dubai Studio City, Dubai Production City, Dubai Knowledge Park, Dubai International Academic City, Dubai Design District (d3), Dubai Industrial City and Dubai Outsource City.

About Virax Biolabs Group Limited.
Founded in 2013, Virax Biolabs Group Limited is an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases.

In addition to distributing an array of in-vitro diagnostic test kits, Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing can be particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

For more information, please visit www.viraxbiolabs.com.


Note to publisher, not for publication

Please login to view this information: Login

Distribution channels: Business General Corporate Expansion
  • Virax Biolabs
  • Please login to view this information
Amaxwire, the smart way to get noticed online